Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancer
A. Marin, A. A. Mamun, H. Akamatsu, D. Ye, d. R. Sudhan, B. P. Brown, L. Eli, K. Marcelain, J. Meiler, C. L. Arteaga, A. B. Hanker
This study identifies secondary HER2 mutations that confer resistance to HER2 kinase inhibitors in HER2-mutant breast cancer by enhancing HER2 signaling and reducing drug binding.
bioRxiv · Sep 23, 2022 · PreprintCancer Biology